PL3580333T3 - Wysokosprawna analiza 3d dla naprowadzania na cel, migracji i cytotoksyczności wobec nowotworu komórki odpowiedzi immunologicznej i leku - Google Patents
Wysokosprawna analiza 3d dla naprowadzania na cel, migracji i cytotoksyczności wobec nowotworu komórki odpowiedzi immunologicznej i lekuInfo
- Publication number
- PL3580333T3 PL3580333T3 PL18706096T PL18706096T PL3580333T3 PL 3580333 T3 PL3580333 T3 PL 3580333T3 PL 18706096 T PL18706096 T PL 18706096T PL 18706096 T PL18706096 T PL 18706096T PL 3580333 T3 PL3580333 T3 PL 3580333T3
- Authority
- PL
- Poland
- Prior art keywords
- migration
- assay
- high throughput
- immune cell
- tumor cytotoxicity
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 238000003556 assay Methods 0.000 title 1
- 230000003013 cytotoxicity Effects 0.000 title 1
- 231100000135 cytotoxicity Toxicity 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 210000002865 immune cell Anatomy 0.000 title 1
- 230000005012 migration Effects 0.000 title 1
- 238000013508 migration Methods 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5029—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell motility
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/02—Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/21—Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/28—Vascular endothelial cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2513/00—3D culture
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762455881P | 2017-02-07 | 2017-02-07 | |
| PCT/US2018/017081 WO2018148208A1 (en) | 2017-02-07 | 2018-02-06 | A high throughput 3d assay for immune cell and drug homing, migration and tumor cytotoxicity |
| EP18706096.7A EP3580333B1 (en) | 2017-02-07 | 2018-02-06 | A high throughput 3d assay for immune cell and drug homing, migration and tumor cytotoxicity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3580333T3 true PL3580333T3 (pl) | 2021-08-02 |
Family
ID=61244768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18706096T PL3580333T3 (pl) | 2017-02-07 | 2018-02-06 | Wysokosprawna analiza 3d dla naprowadzania na cel, migracji i cytotoksyczności wobec nowotworu komórki odpowiedzi immunologicznej i leku |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10859565B2 (pl) |
| EP (1) | EP3580333B1 (pl) |
| JP (1) | JP7242536B2 (pl) |
| CN (1) | CN110312791A (pl) |
| CA (1) | CA3052970A1 (pl) |
| PL (1) | PL3580333T3 (pl) |
| SG (1) | SG11201907277XA (pl) |
| WO (1) | WO2018148208A1 (pl) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022177250A2 (ko) * | 2021-02-16 | 2022-08-25 | 연세대학교 산학협력단 | 고순도의 암 오가노이드, 및 이의 제조방법 |
| US20240269678A1 (en) * | 2021-06-07 | 2024-08-15 | Plexium, Inc. | Transfer dispensers for assay devices with bead size exclusion |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20090094814A (ko) * | 2006-10-10 | 2009-09-08 | 스퀴코어 | 암의 치료 및 진단을 위한 조성물 및 방법 |
| WO2009126524A2 (en) * | 2008-04-08 | 2009-10-15 | Massachusetts Institute Of Technology | Three-dimensional microfluidic platforms and methods of use thereof |
| US8163537B2 (en) * | 2009-01-27 | 2012-04-24 | Corning Incorporated | Nested permeable support device and method for using the nested permeable support device |
| US9790465B2 (en) * | 2013-04-30 | 2017-10-17 | Corning Incorporated | Spheroid cell culture well article and methods thereof |
| JP6832042B2 (ja) * | 2014-10-29 | 2021-02-24 | コーニング インコーポレイテッド | スフェロイド捕捉用挿入体 |
-
2018
- 2018-02-06 PL PL18706096T patent/PL3580333T3/pl unknown
- 2018-02-06 EP EP18706096.7A patent/EP3580333B1/en active Active
- 2018-02-06 CA CA3052970A patent/CA3052970A1/en not_active Abandoned
- 2018-02-06 CN CN201880010756.0A patent/CN110312791A/zh active Pending
- 2018-02-06 US US15/889,766 patent/US10859565B2/en active Active
- 2018-02-06 JP JP2019542516A patent/JP7242536B2/ja active Active
- 2018-02-06 SG SG11201907277XA patent/SG11201907277XA/en unknown
- 2018-02-06 WO PCT/US2018/017081 patent/WO2018148208A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US10859565B2 (en) | 2020-12-08 |
| SG11201907277XA (en) | 2019-09-27 |
| WO2018148208A1 (en) | 2018-08-16 |
| CN110312791A (zh) | 2019-10-08 |
| JP7242536B2 (ja) | 2023-03-20 |
| JP2020510414A (ja) | 2020-04-09 |
| CA3052970A1 (en) | 2018-08-16 |
| US20180224428A1 (en) | 2018-08-09 |
| EP3580333B1 (en) | 2021-04-21 |
| EP3580333A1 (en) | 2019-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL265309A (en) | Bispecific antibodies against MUC16 and CD3 and drug conjugates against MUC16 | |
| ZA201806576B (en) | Antibodies, pharmaceutical compositions and methods | |
| ZA201705923B (en) | Drug conjugates comprising antibodies against claudin 18.2 | |
| IL267129A (en) | New T-cell receptors and immunotherapy using them | |
| PT3347379T (pt) | Anticorpos anti-tígitos, anticorpos anti-pvrig e as suas combinações | |
| ZA202102745B (en) | Anti-ptk7 immune cell cancer therapy | |
| ZA202102740B (en) | Anti-liv1 immune cell cancer therapy | |
| ZA201900664B (en) | T cell receptors and immune therapy using the same | |
| EP3112378A4 (en) | Wt1 antigenic polypeptide, and anti-tumor agent containing said polypeptide | |
| IL257956A (en) | New carbohydrate antibodies, pharmaceutical preparations and their uses | |
| IL268244A (en) | Methods, arrays and their uses | |
| GB201713653D0 (en) | Dosage regimen | |
| IL257434A (en) | Mrka polypeptides, antibodies, and uses thereof | |
| WO2015139020A3 (en) | Vaccine compositions and methods for restoring nkg2d pathway function against cancers | |
| PL3580333T3 (pl) | Wysokosprawna analiza 3d dla naprowadzania na cel, migracji i cytotoksyczności wobec nowotworu komórki odpowiedzi immunologicznej i leku | |
| EP3215193A4 (en) | Dosage regimen for pegylated interferon | |
| SG11202000811RA (en) | Methods for activating immune cells | |
| PL3541911T3 (pl) | Preparaty, ich wytwarzanie i zastosowanie | |
| HUE047919T2 (hu) | Biológiai asszimilációra alkalmas proteo-melanisztikus komplex, készítmény és felhasználásai | |
| SI3500593T1 (sl) | T-celični receptorji in imunska terapija z njihovo uporabo | |
| IL261539A (en) | Multi-drug composition, methods and uses | |
| IL267131A (en) | Novel t cell receptors and immune therapy using the same | |
| HK40061080A (en) | Anti-ptk7 immune cell cancer therapy | |
| HK40060689A (en) | Anti-liv1 immune cell cancer therapy | |
| HK40034991A (en) | Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof |